65,437 trials
Emergence Delirium · Anesthesia Emergence Delirium
Primary: Number of Participants With Emergence Delirium Following Anesthesia in Children — 17; 3 Participants — p=0.001
Suicide
Primary: Number of Eligible Students Who Agree to Randomization — 8; 24; 20; 16 Participants
Autism Spectrum Disorder
Primary: Change in the Autism Behavior Inventory, Short Form (ABI-S) — -2.9; -0.8 score on a scale — p=<0.05
Food Preferences
Primary: Mean Monthly Change in Number of Units of Healthier Foods — -1.32; 0.53 units of healthy food
Chronic Obstructive Pulmonary Disease
Primary: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period — 1.01; 0.776 exacerbation per…
SARS-CoV-2 · Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs) — 38; 80; 90; 92 Participants
Kidney Transplant Rejection
Primary: Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of Treatment — 94; 36 percentage of maximum DSA reduction
Presbyopia
Primary: Mean Binocular Visual Acuity (VA) With Study Lenses at 4 Meters (logMAR) — -0.06; -0.06 logMAR
Eosinophilic Gastritis · Eosinophilic Gastroenteritis · Eosinophilic Duodenitis
Primary: The Safety and Tolerability of AK002 by Evaluating Adverse Events Assessed Using the CTCAE Version 4.03 — 21; 35; 15; 22 Participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) — 25; 12; 6; 15 Participants — p=<0.0001
Feasibility and Acceptability of the TOPS Program · Obesity · Breast Cancer
Primary: Number of Invited Women Who Attended the TOPS (Take Off Pounds Sensibly) Information Session — 45 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Part D: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 13 Participants
Non-Small Cell Lung Cancer
Primary: Progression Free Survival by BICR
Coronavirus
Primary: Success of Administering Plasma — 10; 0 Participants
COVID-19
Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants